Skip to main content

Table 3 Pearson correlations between changes from baseline to week 24 in each estimated fluid volume and clinical variables of interest

From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Variables

ePV

eEV

Coefficient

P value

Coefficient

P value

Systolic blood pressure

0.090

0.542

0.374

0.007

Diastolic blood pressure

0.095

0.520

0.186

0.195

Body mass index

− 0.143

0.333

0.986

 < 0.001

Uric acid

− 0.091

0.546

0.132

0.380

Fasting plasma glucose

0.138

0.361

− 0.081

0.591

Glycohemoglobin

− 0.287

0.048

− 0.027

0.855

eGFRa

0.407

0.005

− 0.091

0.538

UACRa

− 0.011

0.949

0.038

0.817

High-sensitivity troponin Ia

0.177

0.240

0.252

0.091

Total ketone bodiesa

0.029

0.855

− 0.013

0.937

RHIa

− 0.184

0.215

0.155

0.298

  1. RHI reactive hyperemia index. Others see Table 1
  2. aLog-transformed